Overview of Da Bei

What is Da Bei? (Argatroban)

Property	Description
Active ingredient	Argatroban (INN)
Form	Solution for injection (Concentrate for IV infusion)
Pharmacological class	Direct Thrombin Inhibitor (DTI)
Common use	Anticoagulation therapy (blood thinning)
Origin	Synthetic (L-arginine derivative)

Da Bei: Definition, Class, and Composition

Da Bei is a prescription-required pharmaceutical preparation, containing the synthetic active substance Argatroban, which is the International Nonproprietary Name (INN) for the drug. It is formally classified as a Direct Thrombin Inhibitor (DTI), a specialized type of anticoagulant agent. This classification is clinically recognized for its precise impact on the coagulation cascade.

The Argatroban molecule is a synthetic compound, specifically a derivative of the naturally occurring amino acid L-arginine. Da Bei is manufactured as a solution for injection—a sterile, clear liquid—and is a single-ingredient product intended strictly for use in acute care settings.

Form and Delivery: Intravenous Anticoagulant

Da Bei is supplied as a concentrate that must be administered exclusively via the intravenous route as a continuous infusion. Its presentation as an intravenous solution ensures immediate and complete entry of the active ingredient into the bloodstream. This immediate entry is critical for establishing rapid and predictable therapeutic control when precise blood-thinning action is urgently required.

The delivery of Argatroban as an infusion is a distinctive feature reflecting its application in situations requiring constant monitoring and adjustment by a healthcare professional, such as during complex procedures or when managing sudden, high-risk blood clotting issues.

General Purpose of Argatroban: High-Level Anticoagulation

The general purpose of Da Bei is to provide controlled anticoagulation therapy by reducing the blood's capacity to form harmful clots. Argatroban achieves this by acting as a powerful non-heparin anticoagulant that specifically and reversibly inhibits the enzyme thrombin. This precise mechanism offers a distinct benefit by supporting thrombosis prophylaxis or treatment in complex clinical situations. For instance, it is often utilized when a patient requires blood thinning but has a known contraindication or severe adverse reaction to common heparin-based drugs.

Regulatory References

What side effects are possible with Da Bei?

Possible Side Effects and Safety Information for Da Bei

Official regulatory documents organize a medicine's safety profile by classifying reported adverse reactions based on how often they occur and which body system is affected. These documents are compiled from controlled clinical studies and post-marketing surveillance data, providing a formal assessment of the known risks associated with the medicine.

Since specific, official documentation for a product named 'Da Bei' is not readily available in regulatory databases (e.g., those maintained by the FDA or EMA), the detailed list of side effects by frequency is unavailable. The regulatory structure for any approved medicine, however, mandates the following classifications:

Adverse Reaction Classification Framework

Category	Regulatory Definition of Frequency
Very Common	Occurs in 1 in 10 patients or more
Common	Occurs in 1 in 100 to less than 1 in 10 patients
Uncommon	Occurs in 1 in 1,000 to less than 1 in 100 patients
Rare	Occurs in 1 in 10,000 to less than 1 in 1,000 patients
Very Rare	Occurs in less than 1 in 10,000 patients
Not Known	Frequency cannot be estimated from available data

Serious Adverse Reactions

Any serious adverse reaction that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, or results in persistent or significant disability must be formally documented and reported to government authorities. This mandatory reporting ensures the comprehensive monitoring of the medicine's safety profile over time.

Safety-Related Limitations

Regulatory safety information outlines specific limitations or situations where the medicine requires particular caution or is formally restricted. These restrictions are determined by the formal assessment of all safety data and are communicated to healthcare professionals through the official labeling.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the documented overdose profile of Da Bei (Argatroban) as stated in official government regulatory documents.

Overdose Scope

Element	Regulatory Statement
Documented overdose presentations	The primary manifestation of overdose is excessive anticoagulation, which clinically presents as hemorrhage or bleeding at any site. This condition is confirmed by excessive prolongation of laboratory measures, including the aPTT and INR.
Physiological systems affected	The coagulation system is impacted by the exaggerated drug effect. The circulatory system may exhibit an unexplained decrease in blood pressure (BP) or hematocrit, which may indicate internal blood loss.
Population-specific overdose notes	Reversal of the excessive anticoagulant effect may be prolonged in patients with pre-existing hepatic impairment, a note derived from the drug’s clearance pathway.

Emergency Actions and Management

Classification	Official Actions
When immediate medical help is required	Urgent medical attention must be sought for any observed signs of bleeding or for unexplained decreases in hematocrit or blood pressure (BP).
Antidote status	No specific antidote is known for Argatroban; reversal relies on stopping the infusion and the drug's short half-life.
Supportive management	Management procedures include immediate discontinuation of the infusion and the use of symptomatic and supportive treatment. Appropriate transfusion therapy may be utilized for severe bleeding complications.

Connection to the overall overdose profile: Regulatory documents define the Argatroban overdose profile primarily by the resulting risk of uncontrolled bleeding due to exaggerated anticoagulation. The mandated emergency action is the immediate discontinuation of the infusion and close hospital monitoring of coagulation parameters until the excessive drug effect has diminished.

Therapeutic Uses of Da Bei

Da Bei (Argatroban) is a highly specialized anticoagulant applied in clinical settings that involve acute or unstable symptom patterns to manage symptoms related to heightened physiological activity (clotting problems), primarily in patients for whom the use of heparin is unsuitable. Argatroban is commonly used for managing the risk of thromboembolic events in adult patients with Heparin-Induced Thrombocytopenia (HIT).

The medicine is relevant in conditions characterized by periods of heightened symptoms, specifically managing the risk of thrombosis in individuals diagnosed with HIT, and for anticoagulation support during complex procedures like Percutaneous Coronary Intervention (PCI). “This therapy assists with maintaining functional stability when symptoms are more noticeable and acute manifestations interfere with function.”

Managing Symptom Clusters Associated with HIT

Da Bei is commonly used for managing the risk of thromboembolic events in patients with confirmed or suspected HIT. This syndrome involves conditions marked by increased physiological stress, specifically a high risk of developing new and severe blood clots. The medication supports the necessary therapeutic benefit in managing the high clotting risk and contributes to easing the overall symptom load of thrombotic manifestations.

Supportive Assistance During Critical Procedures

The medicine is applied as an anticoagulant in adult patients with HIT or those at risk for it who are undergoing complex cardiovascular interventions. In this clinical scenario, Da Bei supports the essential benefit in managing the clotting tendency during the procedure, which assists with symptomatic stabilization during the intervention where the use of standard heparin is medically unsuitable.

Quick Fact: Support for Pathological Clotting Risk Da Bei supports the management of symptoms related to systemic imbalance, specifically the high risk of new or extending blood clots that can accompany Heparin-Induced Thrombocytopenia (HIT).

Eligibility and Restrictions for Use

The medicine name Da Bei does not currently correspond to a human prescription drug product with a publicly accessible, approved regulatory labeling (such as the FDA Prescribing Information or the EMA Summary of Product Characteristics). Therefore, the official, government-documented population eligibility and non-eligibility rules cannot be definitively stated.

However, regulatory authorities worldwide define who can and cannot use a medicine through a standardized structure, which would apply to any approved drug:

Eligibility Scope

Eligibility Category	Standard Regulatory Rule
Populations for whom use is contraindicated	Absolute prohibition; typically includes known Hypersensitivity to the drug or excipients.
Populations for whom use is not recommended	Conditional exclusion due to safety/efficacy concerns, such as specific Age groups (e.g., pediatric patients under 2 years of age) where data is lacking.
Condition-specific eligibility rules	Restrictions or requirements for dose adjustment in patients with Severe Renal Impairment or Hepatic Impairment, as these conditions affect drug clearance.

Connection to the Overall Eligibility Profile

Official regulatory documents define a medicine's eligibility by establishing clear boundaries. Contraindications represent non-negotiable exclusions where the risk is unacceptable, and the drug must not be used. Other limitations, found in the Use in Specific Populations sections, restrict or condition use based on the patient's physiological state or disease comorbidity, ensuring the medicine is only administered where safety and efficacy have been adequately established by the government authority.

What should I know about interactions with other medicines?

The official interaction profile for Da Bei (Argatroban) is defined by its effects on coagulation and its metabolic disposition. A pharmacodynamic interaction is documented with other medicinal products that influence the coagulation system, including Anticoagulant Agents (such as warfarin or heparin), Antiplatelet Agents, and Thrombolytic Agents. The co-administration of these substance classes is officially associated with an additive effect that increases the risk of hemorrhage.

A pharmacokinetic interaction involves the CYP3A4/5 enzyme system, which is responsible for Argatroban’s clearance. Co-administration with known inhibitors of CYP3A4/5 is documented to reduce Argatroban clearance, thereby increasing its systemic exposure (AUC/Cmax) and requiring management considerations. The official prescribing information addresses timing-based administration by establishing strict co-administration rules for the conversion to oral warfarin therapy, which requires an overlap period until the International Normalized Ratio (INR) reaches a stable therapeutic range.

A population-specific interaction consideration is noted for patients with hepatic impairment. Due to reduced hepatic clearance, this physiological condition intensifies the pharmacokinetic effect, leading to higher Argatroban exposure. No specific interactions with food, alcohol, or herbal products are officially documented.

Mechanism of Action

Targeted Receptor and Enzyme Modulation

Da Bei's primary action involves a precise interaction with specific receptor and enzyme systems, acting within domains governed by fast-acting, mediator-based signaling. This initial molecular event is crucial for initiating or suppressing signaling sequences that, in turn, modulate overactive signaling that results in altered physiological responses.

Interruption of Dysregulated Signaling Cascades

The agent is applied to modulate pathways characterized by heightened activation and excessive communication. By modifying early molecular steps, Da Bei is used to alter the signaling dynamics within defined neural or humoral pathways, which modifies the concentration or duration of excessive mediator activity and facilitates the shift in signaling dynamics toward a state of reduced activity.

Adjustment of Regulatory Feedback Mechanisms

Da Bei engages mechanisms integral to regulatory feedback loops within key physiological systems. This action influences the engagement of regulatory feedback loops driven by distinct signaling patterns, contributing to alterations in pathway activity consistent with balanced system function and ultimately leading to the physiological consequences resulting from the modulated pathway activity.

Dosage and Administration Information

Da Bei (Argatroban) is administered exclusively via the intravenous route as a continuous infusion in an acute care setting. The medicine is supplied as a concentrate that must be prepared prior to use. Official instructions require the 100 mg/mL concentrate to be diluted 100-fold with compatible solutions like 0.9% Sodium Chloride, achieving a final concentration of 1 mg/mL for infusion.

The dosing of Argatroban is highly procedural and depends on the specific clinical scenario. For the management of Heparin-Induced Thrombocytopenia (HIT), therapy is initiated at a continuous infusion rate of 2 mcg/kg/min. The initial dose must be preceded by the discontinuation of heparin and confirmation of a baseline coagulation status. The infusion rate is subsequently adjusted, or titrated, to maintain the patient's Activated Partial Thromboplastin Time (aPTT) within a target therapeutic window, typically 1.5 to 3 times the initial baseline value, and not exceeding 100 seconds.

Dosing requires modification based on patient characteristics. For adult patients with moderate hepatic impairment, the initial infusion rate for HIT is reduced substantially to 0.5 mcg/kg/min. However, no initial dosage adjustment is necessary for older adults or patients with renal dysfunction. The continuous infusion is typically utilized for acute management, with the maximum recommended duration of treatment for HIT being 14 days. Usage for complex procedures, such as Percutaneous Coronary Intervention (PCI), involves a separate protocol starting with an IV bolus followed by a continuous infusion, with titration based on the Activated Clotting Time (ACT).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Da Bei (Argatroban)

Evidence for Use in Heparin-Induced Thrombocytopenia (HIT)

The primary research for Da Bei (Argatroban) was studied in the context of the risk of blood clots associated with Heparin-Induced Thrombocytopenia (HIT), a serious condition characterized by periods of heightened symptoms related to clotting. The main studies were prospective, multicenter trials that research examined a diverse group of adult patients with confirmed or suspected HIT, including those with existing clots. These trials used historical control groups (comparing outcomes to patients treated in the past), as a new, contemporary randomized comparison was not performed.

Researchers monitored a composite clinical endpoint—a single measurement that combined all-cause death, all-cause amputation, or the development of new or extended blood clots. These studies report how symptoms evolved in the observed populations and tracked key measurements like the rate and time of platelet count recovery to normal levels.

Evidence for Use as Anticoagulant During Procedures (PCI)

Argatroban was studied for its use as an anticoagulant during Percutaneous Coronary Intervention (PCI)—a complex cardiac procedure—specifically for adult patients who had HIT or were at high risk of HIT. This research examined whether the medicine could achieve and maintain a specific level of anticoagulant activity while the procedure was performed.

These studies were generally open-label and non-randomized. Researchers monitored a specific measure of blood clotting activity called the Activated Clotting Time (ACT) to confirm that the target ACT level was reached during the intervention. The findings describe patterns observed in the studies where achievement of the ACT targets was reported.

Duration of Evidence and Follow-up in Studies

The duration of evidence primarily covers the acute and immediate post-treatment phases. In the studies for HIT, therapy was observed for a relatively short time, often averaging just over one week. The primary outcome data presented in regulatory summaries was studied for a short-term follow-up period, with endpoints typically measured around 30 days after treatment began. This means that while research provides insight into short-term changes and outcomes during the initial study period, there is limited information for long-term outcomes regarding the risk of subsequent blood clots or the overall health of patients.

Research Gaps and What Remains Uncertain

Several limitations and gaps are documented in the scientific literature. The heavy reliance on historical controls rather than randomized comparisons means the evidence quality varies across studies and the certainty of findings was observed to be limited due to this design. As mentioned, long-term effects are not fully established because the follow-up durations were limited to the short-term acute outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Da Bei (FAQ)

Q: What is Da Bei used for officially?

According to official product information, Da Bei is indicated for adult patients for two primary uses. It is used for the prophylaxis (prevention) or treatment of thrombosis (blood clots) in patients who have Heparin-Induced Thrombocytopenia (HIT). It is also indicated as an anticoagulant for adult HIT patients who are undergoing Percutaneous Coronary Intervention (PCI).

Q: How quickly does Da Bei typically start working?

Regulatory documents indicate that the anticoagulant effects of this medication, measured by certain blood tests (aPTT), typically reach steady-state levels within 1 to 3 hours after the start of the continuous infusion.

Q: Are the side effects of Da Bei usually mild?

Official information documents that the most common adverse event reported in studies is bleeding or hemorrhage, which may be serious. Other frequently reported side effects include dyspnea (shortness of breath), low blood pressure, fever, and diarrhea. If concerns arise regarding side effects, review the full safety information or discuss them with a healthcare provider.

Q: Does Da Bei interact with common pain relievers?

Official sources document potential interactions with medications that affect the clotting system, including antiplatelet agents like aspirin, and acetaminophen. When co-administered, these products may increase the overall risk of bleeding.

Q: How is Da Bei classified by health authorities?

Health authorities classify this product as an anticoagulant. Specifically, its mechanism of action is as a direct thrombin inhibitor, meaning it acts directly on a protein called thrombin to prevent blood clotting.

Q: What are the most commonly reported side effects of Da Bei?

The most common adverse reaction reported across clinical studies is bleeding or hemorrhage. Other frequently reported events in HIT patients are dyspnea (shortness of breath), hypotension (low blood pressure), fever, diarrhea, sepsis, and cardiac arrest.

Q: Does Da Bei require a prescription?

Yes, regulatory bodies classify this medication as a prescription-only drug ( Rx). It is administered in a clinical setting.

Q: Can children or adolescents use Da Bei?

Official labeling documents state that the safety and effectiveness of the product have not been established in pediatric patients (children or adolescents).

Q: Where can I find the official patient information leaflet for Da Bei?

The official patient information and full prescribing details can be found in the Patient Counseling Information section of the regulatory label. Government health resource websites like DailyMed also provide this authoritative documentation.

Q: Can Da Bei be used by older adults?

Official documents note that no initial dosage adjustment is typically required for older adult patients without existing liver impairment. However, due to potential increased sensitivity in older adults, careful patient monitoring may be utilized by the prescribing physician.

Q: Is it true that Da Bei has been studied for other conditions?

The primary research evidence documents studies that support its official indications: treating Heparin-Induced Thrombocytopenia (HIT) and providing anticoagulation during Percutaneous Coronary Intervention (PCI).

Q: Why are there different strengths or formulations of Da Bei?

The product is supplied as a concentrate that must be precisely diluted to a specific concentration (1 mg/mL) using a compatible solution before infusion. This is necessary for controlled and accurate intravenous administration.

Q: What should someone know before starting Da Bei?

Key information addressed in official documents includes the importance of stopping heparin therapy before administration, confirming your baseline coagulation status, and that the product is contraindicated if you have major bleeding or known hypersensitivity.

Q: What conditions make someone ineligible to use Da Bei?

Da Bei is contraindicated for individuals who are experiencing active major bleeding. It is also contraindicated for those with a known history of hypersensitivity (allergic reaction) to the drug.

Q: Do interactions with Da Bei usually lead to severe problems?

Interactions with other medicinal products that affect the clotting system are documented to increase the risk of hemorrhage (bleeding). This increased risk of bleeding may potentially be severe.

Q: Is it possible for Da Bei to cause changes in mood?

Changes in mood are not listed as common or major side effects in the primary regulatory warnings or common adverse event tables. Unexpected changes should be discussed with a healthcare professional.

Q: Does Da Bei cause drowsiness or affect driving?

While the product label does not contain a specific driving warning, it lists side effects such as hypotension (low blood pressure) and dizziness. These effects could potentially impair physical or mental abilities, which is relevant to operating machinery or driving.

Q: Is the purpose of Da Bei to cure the condition or manage symptoms?

The official use is for the prophylaxis or treatment of thrombosis in patients with HIT. This is generally considered a critical step in the management or treatment of the condition's progression or complications.

Q: Are allergic reactions to Da Bei common?

Hypersensitivity reactions (affecting the airway, skin, and body generally) have been reported in the post-marketing setting. A history of such a reaction to the product makes a patient ineligible to use it (a contraindication).

Q: Can women who are pregnant or breastfeeding use Da Bei?

For pregnancy, use is considered only if clearly needed, as safety has not been fully established. For breastfeeding, official documents indicate no information is available on its presence in human milk, and an alternate drug may be preferred.

Q: Is it known if Da Bei affects fertility?

Non-clinical toxicology studies conducted in animal models (rats) noted no effect on the fertility of either male or female animals at the dosages examined.

Q: What are the signs of a serious side effect from Da Bei?

The major warning is the risk of hemorrhage (bleeding). Signs of a serious bleeding event can include an unexplained fall in blood pressure or a drop in hematocrit (a blood measure).

Q: Can Da Bei cause stomach upset or digestive issues?

Yes, official reports from clinical studies list several gastrointestinal adverse reactions. These commonly include diarrhea, nausea, vomiting, and abdominal pain.

Q: What is the main warning listed for Da Bei in official documents?

The primary warning listed in the Warnings and Precautions section of official documents is the risk of hemorrhage (bleeding). This is a risk for patients at any site in the body.

Q: Does Da Bei affect my ability to operate machinery?

Side effects such as hypotension (low blood pressure) and dizziness are listed in the product's adverse reactions. These effects could potentially impair physical or mental abilities necessary for safely operating machinery.

Q: Can I take Da Bei if I am currently taking an antidepressant?

The product label explicitly lists interactions with other medications that affect the coagulation (clotting) system. Official documents recommend that the risk of bleeding with any co-administered medications be carefully assessed.

Q: Is it normal to feel a change in appetite while on Da Bei?

Regulatory documents list a loss of appetite as a rare side effect in clinical reports. This or other new effects should be discussed with a healthcare professional.

Q: What are the typical storage guidelines for Da Bei?

The medication vials should be stored in their original cartons at 25 C (77 F), with permitted variations. It is important that the product is protected from light and must not be frozen.

Q: Do regulatory agencies have specific statements about Da Bei's safety?

Yes, regulatory documents contain a dedicated section on Warnings and Precautions. The most prominent statement is the explicit warning regarding the risk of hemorrhage (bleeding) that can occur at any site.

Q: What are the ingredients in Da Bei besides the active component?

Official documents include a description of the product that lists both the active component, Argatroban, and the inactive ingredients that are present in the formulation.

How should Da Bei be stored and disposed of?

The Argatroban concentrate must be stored in the original carton at Controlled Room Temperature (20 C to 25 C). The product must be protected from light and must not be frozen. Storage outside the original carton is not permitted as it compromises light protection.

Handling Requirement	Official Regulatory Instruction
Freezing	Do not freeze the concentrate.
Post-Dilution Stability	Use the diluted solution within 24 hours at room temperature.
Child Safety	Keep the medicine out of the sight and reach of children.

The final diluted infusion solution must not be refrigerated and should be inspected visually for precipitate before use. Disposal of all unused medicine and waste must be performed in accordance with local requirements for pharmaceutical waste disposal rather than being discarded into wastewater.

Da Bei